|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003864,
umls-concept:C0008976,
umls-concept:C0023981,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0035647,
umls-concept:C0087111,
umls-concept:C0332162,
umls-concept:C0332185,
umls-concept:C1514983,
umls-concept:C1521840,
umls-concept:C1524063,
umls-concept:C1707689,
umls-concept:C2587213
|
|
pubmed:dateCreated |
2009-6-29
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Early and intensive treatment is important to inducing remission and preventing joint damage in patients with rheumatoid arthritis. While intensive combination therapy (Disease Modifying Anti-rheumatic Drugs and/or biologicals) is the most effective, rheumatologists in daily clinical practice prefer to start with monotherapy methotrexate and bridging corticosteroids. Intensive treatment should be started as soon as the first symptoms manifest, but at this early stage, ACR criteria may not be fulfilled, and there is a danger of over-treatment. We will therefore determine which induction therapy is most effective in the very early stage of persistent arthritis. To overcome over-treatment and under-treatment, the intensity of induction therapy will be based on a prediction model that predicts patients' propensity for persistent arthritis.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-10090194,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-10109801,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-10334255,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-10513799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-10556269,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-10609068,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-10986305,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-11690569,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-11840437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-12115216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-12115219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-15113999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-15748099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-16258899,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-16396980,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-16783865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-17195186,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-17225293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-17265478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-17371885,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-17576784,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-17915098,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-17934098,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-18025440,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-18662933,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-18688915,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-18821663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-19137203,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-2256738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-3358796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-6488708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-7779122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-8507213,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-8546736,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-8605266,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-8609945,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-9251634,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19538718-9817123
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2474
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
71
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19538718-Antirheumatic Agents,
pubmed-meshheading:19538718-Arthritis, Rheumatoid,
pubmed-meshheading:19538718-Clinical Protocols,
pubmed-meshheading:19538718-Clinical Trials as Topic,
pubmed-meshheading:19538718-Drug Combinations,
pubmed-meshheading:19538718-Drug Costs,
pubmed-meshheading:19538718-Early Diagnosis,
pubmed-meshheading:19538718-Humans,
pubmed-meshheading:19538718-Longitudinal Studies,
pubmed-meshheading:19538718-Outcome Assessment (Health Care),
pubmed-meshheading:19538718-Predictive Value of Tests,
pubmed-meshheading:19538718-Prognosis,
pubmed-meshheading:19538718-Prospective Studies,
pubmed-meshheading:19538718-Research Design,
pubmed-meshheading:19538718-Risk Assessment,
pubmed-meshheading:19538718-Severity of Illness Index,
pubmed-meshheading:19538718-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial.
|
|
pubmed:affiliation |
Department of Rheumatology, Erasmus MC, University Medical Center, Dr Molewaterplein, Rotterdam, The Netherlands. s.claessen@kaze.nl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
